Skip to content
UK
-
UK approves Gilead’s twice-yearly HIV prevention shot, Yeytuo
With this latest authorisation, individuals now have access to a long-acting option for prevention rather than daily pill-based regimens.
-
GSK expands its respiratory portfolio with FDA-approved long-acting biologic exdensur
The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.
-
MHRA approves Roche’s Itovebi for advanced breast cancer treatment
This oral formulation offers a more convenient delivery method compared to intravenous treatments.